Neutralizing antibodies to gp120 and their use

US10562960B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Mark Connors · Bethesda, US
• Jinghe Huang · Bethesda, US
• Byong Ha Kang · San Francisco, US
• John Mascola · Rockville, US
• Elise Ishida · Aiea, US
• Tongqing Zhou · Boyds, US
• Peter Kwong · Washington, US
• Anqi Zheng · Boyds, US

Key dates

• Filing date: Mar 18, 2016
• Grant date: Feb 18, 2020
• Expiry date: Jun 14, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.